登录 | 注册    关注公众号  
微信公众号
搜索
 > 【CXCR3】

CXCR3信息

英文名称:C-X-C motif chemokine receptor 3
中文名称:C-X-C基序趋化因子受体3
靶点别称:CKR-L2,G protein-coupled receptor 9,IP-10 receptor,CXCR-3,CXC-R3,CXCR3,C-X-C Motif Chemokine Receptor 3,Interferon-Inducible Protein 10 Receptor,GPR9,C-X-C Chemokine Receptor Type 3,Chemokine Receptor 3,CD183 Antigen,CMKAR3,Chemokine (C-X-C Motif) Receptor 3,Mig Receptor,IP10-R,CD182,CD183,Mig-R,MigR,Receptors, CXCR3
上市药物数量:0
临床药物数量:2
最高研发阶段:临床一期

CXCR3产品列表

ACRO质量管理体系
 
评论(0)
 

CXCR3分子别名

CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR

CXCR3分子背景

Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

CXCR3临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
OCU-110 OCU-110; OCU-10-C-110 临床一期 Ocugenix Corp 年龄相关性黄斑变性 详情
ACT-777991 ACT-777991 临床一期 Idorsia Pharmaceuticals Ltd 一型糖尿病, 炎性疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定